- Home
- ISDR vs IFRX Comparison
ISDR vs IFRX Comparison
Compare ISDR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISDR
- IFRX
- Stock Information
- Founded
- ISDR 1988
- IFRX 2007
- Country
- ISDR United States
- IFRX Germany
- Employees
- ISDR N/A
- IFRX N/A
- Industry
- ISDR Publishing
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ISDR Consumer Discretionary
- IFRX Health Care
- Exchange
- ISDR Nasdaq
- IFRX Nasdaq
- Market Cap
- ISDR N/A
- IFRX 122.5M
- IPO Year
- ISDR N/A
- IFRX 2017
- Fundamental
- Price
- ISDR $9.65
- IFRX $2.08
- Analyst Decision
- ISDR
- IFRX Strong Buy
- Analyst Count
- ISDR 0
- IFRX 1
- Target Price
- ISDR N/A
- IFRX $8.00
- AVG Volume (30 Days)
- ISDR 8.7K
- IFRX 290.3K
- Earning Date
- ISDR 11-07-2024
- IFRX 11-08-2024
- Dividend Yield
- ISDR N/A
- IFRX N/A
- EPS Growth
- ISDR N/A
- IFRX N/A
- EPS
- ISDR N/A
- IFRX N/A
- Revenue
- ISDR $29,141,000.00
- IFRX $187,930.00
- Revenue This Year
- ISDR N/A
- IFRX $311.47
- Revenue Next Year
- ISDR N/A
- IFRX $227.11
- P/E Ratio
- ISDR N/A
- IFRX N/A
- Revenue Growth
- ISDR N/A
- IFRX 177.12
- 52 Week Low
- ISDR $7.61
- IFRX $1.17
- 52 Week High
- ISDR $19.03
- IFRX $2.44
- Technical
- Relative Strength Index (RSI)
- ISDR 41.79
- IFRX 67.84
- Support Level
- ISDR $9.41
- IFRX $1.51
- Resistance Level
- ISDR $9.77
- IFRX $2.15
- Average True Range (ATR)
- ISDR 0.36
- IFRX 0.25
- MACD
- ISDR -0.02
- IFRX 0.05
- Stochastic Oscillator
- ISDR 13.82
- IFRX 62.50
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.